Aspire Biopharma Holdings (ASBP) Cash from Financing Activities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Cash from Financing Activities data on file, last reported at $7.9 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 155.03% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 243.29% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 2199.19% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $7.9 million, up from -$16526.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for ASBP reached as high as $296.6 million in Q1 2022 and fell as low as -$632968.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $28.2 million across 5 years, with a median of $229084.0 in 2024.
• Across the five-year window, Cash from Financing Activities slumped 416.0% in 2024 and soared 1250.79% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $296.6 million in 2022, then slumped by 99.95% to $155848.0 in 2023, then slumped by 416.0% to -$492477.0 in 2024, then jumped by 96.64% to -$16526.0 in 2025, then surged by 47852.89% to $7.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $7.9 million in Q1 2026, -$16526.0 in Q4 2025, and $2.8 million in Q3 2025.